Even though all the molecular mechanisms through which these compounds act in the ovary have not been fully explained, this study suggests a potential novel approach for women with PCOS phenotype D, as they may not benefit from the canonical therapies commonly recommended to PCOS patients, such as insulin sensitizers. This evidence concerns the gene INS and polycystic ovary syndrome.